

# Don S Dizon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/737660/publications.pdf>

Version: 2024-02-01

212  
papers

7,130  
citations

57681

46  
h-index

78623

77  
g-index

216  
all docs

216  
docs citations

216  
times ranked

10330  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Social Media and Oncology: The Time Is Now. JCO Oncology Practice, 2022, 18, 525-527.   | 1.4 | 4         |
| 2  | Analysis of Hematology and Oncology Fellowship Website Content and Diversity Representation. JCO Oncology Practice, 2022, , OP2100623.  | 1.4 | 4         |
| 3  | eSyM: An Electronic Health Recordâ€‘Integrated Patient-Reported Outcomesâ€‘Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Informatics, 2022, 6, e2100137.  | 1.0 | 19        |
| 4  | Netiquette for social media engagement for oncology professionals. Future Oncology, 2022, 18, 1133-1141.  | 1.1 | 3         |
| 5  | Ethics-Centered Guidelines for Social Media Use by Oncology Professionals: A Call to Action. JCO Oncology Practice, 2022, 18, 537-540.  | 1.4 | 2         |
| 6  | Using Social Media for Clinical Research: Recommendations and Examples From the Brown-Lifespan Center for Digital Health. Journal of Medical Internet Research, 2022, 24, e35804.   | 2.1 | 2         |
| 7  | Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. Trials, 2022, 23, . | 0.7 | 9         |
| 8  | The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discovery, 2022, 12, 1620-1624.  | 7.7 | 9         |
| 9  | Social Media and the Quest for Equity and Diversity in Oncology: On Safe Spaces and the Concept of the Public Physician. JCO Oncology Practice, 2022, 18, 572-577.  | 1.4 | 1         |
| 10 | Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.  | 2.6 | 67        |
| 11 | â€‘Going Flatâ€‘After Mastectomy: Patient-Reported Outcomes by Online Survey. Annals of Surgical Oncology, 2021, 28, 2493-2505.   | 0.7 | 28        |
| 12 | Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer. Breast Cancer Research and Treatment, 2021, 186, 667-676.   | 1.1 | 5         |
| 13 | Abstract PS7-57: Patient risk factors for loss to breast oncologic follow up. , 2021, , .   |     | 0         |
| 14 | Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. JCO Oncology Practice, 2021, 17, e336-e342.  | 1.4 | 7         |
| 15 | People with cancer are likely to accept the COVID-19 vaccine, but politics tracks with attitudes: An inspire and COSMO survey.. Journal of Clinical Oncology, 2021, 39, 1531-1531.  | 0.8 | 11        |
| 16 | Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers, 2021, 13, 3196.                         | 1.7 | 3         |
| 17 | Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organizationâ€™s Response for Readiness, Mitigation, and Resilience. JCO Oncology Practice, 2021, 17, 365-374.                                   | 1.4 | 53        |
| 18 | Sporadic uterine Lymphangi leiomyomatosis (LAM): Report of a unique case arising in the lower uterine segment with short review. Gynecologic Oncology Reports, 2021, 37, 100812.  | 0.3 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 204-210.  | 0.6 | 20        |
| 20 | New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab. <i>Clinical Breast Cancer</i> , 2020, 20, 246-252.  | 1.1 | 6         |
| 21 | Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.          | 0.6 | 35        |
| 22 | Waging War on War Metaphors in Cancer and COVID-19. <i>JCO Oncology Practice</i> , 2020, 16, 624-627.  | 1.4 | 21        |
| 23 | Clinical Trials in the Era of Digital Engagement: A SWOG Call to Action. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 254-258.  | 1.0 | 5         |
| 24 | Now, More Than Ever, Is the Time for Early and Frequent Advance Care Planning. <i>Journal of Clinical Oncology</i> , 2020, 38, 2956-2959.  | 0.8 | 9         |
| 25 | A social media survey of women who do not pursue reconstruction after mastectomy for breast cancer: Characterizing the "Going Flat" movement. <i>Breast Journal</i> , 2020, 26, 1455-1457.                   | 0.4 | 14        |
| 26 | Sexual Health Issues in Cancer Survivors. <i>Seminars in Oncology Nursing</i> , 2020, 36, 150981.  | 0.7 | 8         |
| 27 | Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2031202.   | 2.8 | 10        |
| 28 | Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11545-11545.  | 0.8 | 1         |
| 29 | Endometrial Cancer Genetic Classification and Its Clinical Application. , 2020, , 23-47.   |     | 0         |
| 30 | Does age contribute to distress in new geriatric oncology patients?. <i>Journal of Clinical Oncology</i> , 2020, 38, e24023-e24023.  | 0.8 | 0         |
| 31 | Appropriateness of opioid prescribing in cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24129-e24129.  | 0.8 | 0         |
| 32 | Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19046-e19046.       | 0.8 | 0         |
| 33 | Distress: Characterizing What Causes the Thermometer to Shift in Patients with Newly Diagnosed Breast Cancer Attending a Multidisciplinary Clinic. <i>Annals of Surgical Oncology</i> , 2019, 26, 3204-3209. | 0.7 | 7         |
| 34 | Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 1731.   | 3.4 | 150       |
| 35 | Physician Perceptions of the Use of Social Media for Recruitment of Patients in Cancer Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1911528.  | 2.8 | 21        |
| 36 | Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.                                | 1.0 | 23        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of MÅ¼llerian origin. <i>Gynecologic Oncology</i> , 2019, 153, 223-229.   | 0.6 | 7         |
| 38 | Protecting Patient Privacy in Narratives: The Lifespan-Brown Checklist for Appropriate Use of Patient Narratives. <i>Oncologist</i> , 2019, 24, 285-287.   | 1.9 | 1         |
| 39 | Prostate Cancer Social Media: In YouTube We Trust?. <i>European Urology</i> , 2019, 75, 568-569.   | 0.9 | 18        |
| 40 | Desire to address costs at time of treatment decisions among patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6640-6640.   | 0.8 | 2         |
| 41 | The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11622-11622.  | 0.8 | 0         |
| 42 | After cancer, whatâ€™s more important? The survivorship care plan or the survivorship care visit?. <i>Journal of Clinical Oncology</i> , 2019, 37, 11618-11618.  | 0.8 | 0         |
| 43 | Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 313-315.  | 0.6 | 30        |
| 44 | Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline <i>BRCA1</i> Mutation. <i>Oncologist</i> , 2018, 23, 650-653.   | 1.9 | 8         |
| 45 | Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. <i>Practical Radiation Oncology</i> , 2018, 8, 206-212.   | 1.1 | 3         |
| 46 | Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. <i>Cancer</i> , 2018, 124, 2438-2446.   | 2.0 | 28        |
| 47 | Axillary Ultrasound Fine Needle Aspiration Biopsy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 702-707.   | 0.6 | 4         |
| 48 | A Multimodal Intervention Enhances Sexual Function and Quality of Life (QOL) in Hematopoietic Stem Cell Transplant (HCT) Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S252.   | 2.0 | 0         |
| 49 | Palliative Total Pelvic Exenteration for Gynecologic Cancers: A Cross-sectional Study of Society of Gynecologic Oncology Members. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1796-1804.  | 1.2 | 6         |
| 50 | Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-8.  | 1.0 | 7         |
| 51 | Sexuality, fertility and pregnancy following breast cancer treatment. <i>Gland Surgery</i> , 2018, 7, 404-410.   | 0.5 | 12        |
| 52 | Survivorship care planning in gynecologic oncologyâ€™ perspectives from patients, caregivers, and health care providers. <i>Journal of Cancer Survivorship</i> , 2018, 12, 762-774.  | 1.5 | 19        |
| 53 | A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2018, 151, 202-207. | 0.6 | 10        |
| 54 | A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 274-281.  | 0.6 | 105       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Cluster Analysis Demonstrates the Need to Individualize Care for Cancer Survivors. <i>Oncologist</i> , 2018, 23, 1474-1481.  | 1.9 | 13        |
| 56 | The Needs of Women Treated for Ovarian Cancer: Results From a #gynccsm Twitter Chat. <i>Journal of Patient-centered Research and Reviews</i> , 2018, 5, 149-157.   | 0.6 | 15        |
| 57 | Cluster analysis to demonstrate the need to individualize care for cancer survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 62-62.   | 0.8 | 0         |
| 58 | Survivorship care planning in gynecologic oncology: Perspectives from patients, caregivers, and health care providers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 63-63.   | 0.8 | 2         |
| 59 | Considering cost and value with patients in clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18905-e18905.  | 0.8 | 0         |
| 60 | Identifying sexual orientation in the medical record: A first step towards understanding gynecologic cancer disparities.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18641-e18641.   | 0.8 | 0         |
| 61 | Advance care planning as a shared endeavor: completion of ACP documents in a multidisciplinary cancer program. <i>Psycho-Oncology</i> , 2017, 26, 67-73.   | 1.0 | 21        |
| 62 | Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.   | 0.8 | 318       |
| 63 | Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 92-120.   | 2.3 | 136       |
| 64 | The emerging role of professional social media use in oncology. <i>Future Oncology</i> , 2017, 13, 1281-1285.  | 1.1 | 32        |
| 65 | A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 236-242. | 0.6 | 17        |
| 66 | A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). <i>Annals of Oncology</i> , 2017, 28, 505-511.                          | 0.6 | 57        |
| 67 | A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.                            | 0.6 | 7         |
| 68 | Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection. <i>Gynecologic Oncology</i> , 2017, 144, 241-242.   | 0.6 | 6         |
| 69 | What's the Harm?. <i>Oncologist</i> , 2017, 22, 1006-1007.   | 1.9 | 2         |
| 70 | PARP inhibitors for targeted treatment in ovarian cancer. <i>Lancet, The</i> , 2017, 390, 1929-1930.   | 6.3 | 30        |
| 71 | Twitter 101 and beyond: introduction to social media platforms available to practicing hematologist/oncologists. <i>Seminars in Hematology</i> , 2017, 54, 177-183.  | 1.8 | 13        |
| 72 | Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. <i>Seminars in Hematology</i> , 2017, 54, 198-204.  | 1.8 | 29        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter?. <i>Annals of Surgical Oncology</i> , 2017, 24, 3133-3140.   | 0.7 | 40        |
| 74 | Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 177-178. | 2.0 | 14        |
| 75 | Reply to the letter to the editor "Integrating communication as a core skill in the global curriculum for medical oncology" by Horlait et al.. <i>Annals of Oncology</i> , 2017, 28, 905-906.  | 0.6 | 1         |
| 76 | Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and <i>POLE</i> -mutated recurrent or persistent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5615-TPS5615. | 0.8 | 6         |
| 77 | A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10013-10013.  | 0.8 | 0         |
| 78 | A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 191-191.  | 0.8 | 0         |
| 79 | Cervical cancer control in Latin America: A call to action. <i>Cancer</i> , 2016, 122, 502-514.  | 2.0 | 32        |
| 80 | Breast Cancer Risk Assessment. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 156-157.  | 0.2 | 0         |
| 81 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.   | 2.0 | 82        |
| 82 | Social media in cancer care: highlights, challenges & opportunities. <i>Future Oncology</i> , 2016, 12, 1549-1552.   | 1.1 | 40        |
| 83 | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.                           | 0.8 | 318       |
| 84 | Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.                                       | 0.6 | 208       |
| 85 | Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. <i>Clinical Obstetrics and Gynecology</i> , 2016, 59, 756-771.   | 0.6 | 2         |
| 86 | Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care. <i>Current Oncology Reports</i> , 2016, 18, 11.   | 1.8 | 23        |
| 87 | Sexuality After Cancer: A Model for Male Survivors. <i>Journal of Sexual Medicine</i> , 2016, 13, 70-78.   | 0.3 | 32        |
| 88 | Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. <i>Seminars in Radiation Oncology</i> , 2016, 26, 3-8.  | 1.0 | 20        |
| 89 | A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. <i>Gynecologic Oncology</i> , 2016, 141, 108-112.  | 0.6 | 6         |
| 90 | Chemotherapy in ovarian germ cell tumors: A systematic review. <i>Gynecologic Oncology</i> , 2016, 141, 602-607.   | 0.6 | 24        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Disease-Specific Hashtags for Online Communication About Cancer Care. <i>JAMA Oncology</i> , 2016, 2, 392.  | 3.4 | 91        |
| 92  | Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.   | 0.8 | 141       |
| 93  | ADX51001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NCIC125 study. <i>Journal of Clinical Oncology</i> , 2016, 34, 5516-5516.                                      | 0.8 | 19        |
| 94  | Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs). <i>Journal of Clinical Oncology</i> , 2016, 34, e18007-e18007. | 0.8 | 0         |
| 95  | A description of a small cohort of Argentinian women presenting with cervical cancer (CC) highlighting the need for CC control in Latin America (LA). <i>Journal of Clinical Oncology</i> , 2016, 34, e17026-e17026.  | 0.8 | 0         |
| 96  | A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study. <i>Journal of Clinical Oncology</i> , 2016, 34, 5585-5585.   | 0.8 | 0         |
| 97  | Uterine Sarcoma, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1321-1331.  | 2.3 | 58        |
| 98  | Development of a Breast Cancer Advocacy and Access Health Program in Nicaragua. <i>Breast Journal</i> , 2015, 21, 570-571.  | 0.4 | 1         |
| 99  | Advances in the Management of Recurrent Endometrial Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 206-212.   | 0.6 | 74        |
| 100 | Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 18-23.   | 0.6 | 64        |
| 101 | Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv442.   | 3.0 | 13        |
| 102 | Delay in chemotherapy administration adversely affects overall survival in elderly ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 136, 403.   | 0.6 | 0         |
| 103 | Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 786-809.  | 0.8 | 102       |
| 104 | Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2305-2314.   | 3.2 | 85        |
| 105 | Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 401-405.   | 0.6 | 51        |
| 106 | Sexual Recovery After Cancer. <i>Current Sexual Health Reports</i> , 2015, 7, 63-69.  | 0.4 | 1         |
| 107 | Toward Eubiosia: Bridging Oncology and Palliative Care. <i>Oncologist</i> , 2015, 20, 5-6.  | 1.9 | 1         |
| 108 | Progress and remaining challenges for cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , 2015, 16, 1405-1438.  | 5.1 | 142       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.. Journal of Clinical Oncology, 2015, 33, 5500-5500. | 0.8 | 34        |
| 110 | Disease-specific hashtags for online communication about cancer care.. Journal of Clinical Oncology, 2015, 33, 6520-6520.  | 0.8 | 6         |
| 111 | Breast cancer and sexual function. Translational Andrology and Urology, 2015, 4, 160-8.  | 0.6 | 39        |
| 112 | Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 5515-5515.  | 0.8 | 0         |
| 113 | Survivorship in Gynecologic Cancer: Enduring the Treatment toward a New Normal. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e288-e294.  | 1.8 | 4         |
| 114 | Improving quality of life in female cancer survivors: current status and future questions. Future Oncology, 2014, 10, 1015-1026.   | 1.1 | 4         |
| 115 | A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 44-48.   | 0.6 | 16        |
| 116 | Management and outcomes for elderly women with vulvar cancer over time. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 719-727.  | 1.1 | 25        |
| 117 | A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 441-445.  | 0.6 | 69        |
| 118 | Sexual Health as a Survivorship Issue for Female Cancer Survivors. Oncologist, 2014, 19, 202-210.  | 1.9 | 99        |
| 119 | Narratives in Oncology. Oncologist, 2014, 19, 789-789.   | 1.9 | 0         |
| 120 | Sexual Dysfunction in Female Cancer Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 101-106.   | 0.6 | 70        |
| 121 | My Father's Final Lesson. Oncologist, 2014, 19, 1110-1111.   | 1.9 | 0         |
| 122 | Guilt and the Burden on Oncology Providers. Oncologist, 2014, 19, 441-442.   | 1.9 | 1         |
| 123 | State of the science in cervical cancer: Where we are today and where we need to go. Cancer, 2014, 120, 2282-2288.   | 2.0 | 36        |
| 124 | Cervical Cancer Prevention: Asian-American Women's Knowledge and Participation in Screening Practices. Women's Health Issues, 2014, 24, e231-e236.   | 0.9 | 18        |
| 125 | Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmacogenomics and Personalized Medicine, 2014, 7, 95.  | 0.4 | 13        |
| 126 | Survivorship: Nutrition and Weight Management, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1396-1406.   | 2.3 | 31        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Survivorship: Immunizations and Prevention of Infections, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1098-1111.  | 2.3 | 16        |
| 128 | Survivorship: Healthy Lifestyles, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1222-1237.  | 2.3 | 47        |
| 129 | Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1526-1531.  | 2.3 | 14        |
| 130 | A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265).. Journal of Clinical Oncology, 2014, 32, TPS5617-TPS5617. | 0.8 | 5         |
| 131 | Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 3075-3075.  | 0.8 | 1         |
| 132 | Advances in the diagnosis and treatment of uterine sarcomas. Discovery Medicine, 2014, 17, 339-45.   | 0.5 | 9         |
| 133 | Why DOMA is unconstitutional, beyond the traditional views of same sex relationships. Journal of Assisted Reproduction and Genetics, 2013, 30, 861-861.  | 1.2 | 0         |
| 134 | The effects of age on treatment and outcomes in women with stages IB1â€“IIB cervical cancer. Journal of Geriatric Oncology, 2013, 4, 374-381.  | 0.5 | 4         |
| 135 | Outcomes for Women Receiving Bevacizumab forÂTreatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center. Clinical Ovarian and Other Gynecologic Cancer, 2013, 6, 21-24.                                  | 0.1 | 1         |
| 136 | Pushing the bar in treatment of cervical cancer: What can comprehensive cancer centers do on their own?. Gynecologic Oncology, 2013, 131, 464-466.   | 0.6 | 2         |
| 137 | Sexual dysfunction in women with cancer. Fertility and Sterility, 2013, 100, 916-921.  | 0.5 | 73        |
| 138 | Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. BMJ Open, 2013, 3, e003138.   | 0.8 | 27        |
| 139 | Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstetrics and Gynecology International, 2013, 2013, 1-10.  | 0.5 | 25        |
| 140 | Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. BMJ, The, 2013, 347, f7066-f7066.   | 3.0 | 94        |
| 141 | Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 519-525.  | 0.6 | 2         |
| 142 | Clear cell cancer of the ovary. Current Opinion in Oncology, 2013, 25, 553-557.  | 1.1 | 14        |
| 143 | Locally Advanced Vulvar Cancer in Elderly Women. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 279-282.   | 0.6 | 7         |
| 144 | Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 1219-1225.                                    | 1.2 | 18        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Preparing for Survivorship: Quality of Life in Breast Cancer Survivors. <i>Journal of Sexual Medicine</i> , 2013, 10, 16-20.   | 0.3 | 14        |
| 146 | Is Tumor Board Relevant?. <i>Breast Journal</i> , 2013, 19, 351-353.   | 0.4 | 4         |
| 147 | The Power of Words: Discussing Decision Making and Prognosis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 442-446.  | 1.8 | 7         |
| 148 | Effect of female-dominant support networks on end-of-life decision making among women with advanced or recurrent cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6590-6590.   | 0.8 | 0         |
| 149 | Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6579-6579.  | 0.8 | 0         |
| 150 | The role of oncologic health care providers in end of life discussions for women with recurrent gynecologic or breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20543-e20543.  | 0.8 | 0         |
| 151 | Practical Guidance: The Use of Social Media In Oncology Practice. <i>Journal of Oncology Practice</i> , 2012, 8, e114-e124.  | 2.5 | 140       |
| 152 | Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 979-986.  | 1.2 | 78        |
| 153 | Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2012, 127, 141-146.  | 0.6 | 80        |
| 154 | Medical Therapy of Endometrial Cancer. <i>Drugs</i> , 2012, 72, 705-713.   | 4.9 | 36        |
| 155 | Antimitotic Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 607-628.   | 0.9 | 14        |
| 156 | Novel Antiangiogenic Therapies in Ovarian Cancer. <i>Women's Health</i> , 2012, 8, 447-453.  | 0.7 | 3         |
| 157 | Feels good, looks better: Proportion of women completing all stages of breast reconstruction after mastectomy for breast cancer treatment or prophylaxis. <i>Gynecologic Oncology</i> , 2012, 125, S47-S48.  | 0.6 | 0         |
| 158 | A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 125, 367-371. | 0.6 | 90        |
| 159 | The effects of age on treatment and outcomes in women with stage IB-IIb cervical cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5100-5100.   | 0.8 | 0         |
| 160 | Breast Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 150-156.  | 0.6 | 5         |
| 161 | Placental Mesenchymal Dysplasia Presenting as a Twin Gestation With Complete Molar Pregnancy. <i>Obstetrics and Gynecology</i> , 2011, 118, 445-449.   | 1.2 | 22        |
| 162 | Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making?. <i>Health Expectations</i> , 2011, 14, 84-91.   | 1.1 | 140       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 123, 182-186. | 0.6 | 15        |
| 164 | Patterns of Cellular Distribution with the Sentinel Node Positive for Breast Cancer. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-4.  | 0.6 | 0         |
| 165 | New advances in the treatment of endometrial cancer. <i>Clinical Investigation</i> , 2011, 1, 413-422.   | 0.0 | 1         |
| 166 | Evaluation of the Female with Sexual Dysfunction. , 2011, , 351-356.   |     | 0         |
| 167 | Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program. <i>Gynecologic Oncology</i> , 2010, 116, 295-300.  | 0.6 | 36        |
| 168 | Treatment options for advanced endometrial carcinoma. <i>Gynecologic Oncology</i> , 2010, 117, 373-381.  | 0.6 | 77        |
| 169 | Clinical Characteristics and Choices Regarding Risk-Reducing Surgery in BRCA Mutation Carriers. <i>Gynecologic and Obstetric Investigation</i> , 2010, 69, 270-273.  | 0.7 | 18        |
| 170 | Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Malignant Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 154-159.   | 0.8 | 96        |
| 171 | HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 243-250.  | 1.4 | 13        |
| 172 | Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1215-1223.   | 0.8 | 172       |
| 173 | Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 343-347.  | 1.2 | 4         |
| 174 | Advance Care Planning Decisions of Women with Cancer: Provider Recognition and Stability of Choices. <i>Journal of Psychosocial Oncology</i> , 2009, 27, 383-395.  | 0.6 | 4         |
| 175 | Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P. <i>Journal of Clinical Oncology</i> , 2009, 27, 3104-3108.  | 0.8 | 106       |
| 176 | New-generation platinum agents for solid tumors. <i>Future Oncology</i> , 2009, 5, 33-42.  | 1.1 | 101       |
| 177 | Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4693-4700.              | 0.8 | 95        |
| 178 | Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2 m <sup>2</sup> . <i>Gynecologic Oncology</i> , 2009, 114, 53-56.   | 0.6 | 27        |
| 179 | Quality of Life after Breast Cancer: Survivorship and Sexuality. <i>Breast Journal</i> , 2009, 15, 500-504.  | 0.4 | 76        |
| 180 | Sexual Ramifications of Medical Illness. <i>Clinical Obstetrics and Gynecology</i> , 2009, 52, 691-701.  | 0.6 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | The Differential Diagnosis of Dyspnea in a Woman with Metastatic Breast Cancer-Consideration Beyond Pulmonary Embolism. <i>Breast Journal</i> , 2008, 14, 90-91.   | 0.4 | 2         |
| 182 | Society of Gynecologic Oncologists Position Paper: Breast Cancer Care. <i>Gynecologic Oncology</i> , 2008, 110, 7-12.  | 0.6 | 2         |
| 183 | Regional Chemotherapy: A Focus on Hepatic Artery Infusion for Colorectal Cancer Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 759-771.   | 0.6 | 32        |
| 184 | HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 1363-1369.   | 2.5 | 1         |
| 185 | For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 39-42.  | 0.6 | 11        |
| 186 | Oral Thalidomide as Palliative Chemotherapy in Women with Advanced Ovarian Cancer. <i>Journal of Palliative Medicine</i> , 2007, 10, 61-66.  | 0.6 | 15        |
| 187 | Does One Person Provide It All? Primary Support and Advanced Care Planning for Women With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1412-1416.   | 0.8 | 12        |
| 188 | Defining social support systems for women with breast cancer. <i>American Journal of Surgery</i> , 2007, 194, 501-503.   | 0.9 | 15        |
| 189 | Clinical characteristics of women presenting with skin-only recurrence of breast cancer. <i>American Journal of Surgery</i> , 2007, 194, 494-496.  | 0.9 | 5         |
| 190 | Sex, Intimacy, and the Gynecologic Oncologist. <i>Journal of Psychosocial Oncology</i> , 2007, 25, 61-70.  | 0.6 | 82        |
| 191 | Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. <i>Gynecologic Oncology</i> , 2007, 105, 81-83. | 0.6 | 55        |
| 192 | A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2007, 25, 335-341.  | 1.2 | 15        |
| 193 | Role of ultrasound-guided axillary fine-needle aspiration in the management of invasive breast cancer. <i>American Journal of Surgery</i> , 2006, 192, 458-461.  | 0.9 | 34        |
| 194 | Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. <i>Gynecologic Oncology</i> , 2006, 100, 149-151.   | 0.6 | 39        |
| 195 | Two for good measure: Six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 417-421.                               | 0.6 | 13        |
| 196 | Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2006, 103, 72-74.                  | 0.6 | 14        |
| 197 | Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. <i>Gynecologic Oncology</i> , 2006, 103, 261-270.                           | 0.6 | 115       |
| 198 | Ovarian Cancer Associated with Testosterone Supplementation in a Female-to-Male Transsexual Patient. <i>Gynecologic and Obstetric Investigation</i> , 2006, 62, 226-228.   | 0.7 | 81        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5943-5949.  | 0.8 | 118       |
| 200 | Dyspnea during Thalidomide Treatment for Advanced Ovarian Cancer. <i>Annals of Pharmacotherapy</i> , 2005, 39, 962-965.  | 0.9 | 11        |
| 201 | Incorporating Targeted Treatments into Standard Regimens: Whither the Role of Established Doses?. <i>Cancer Investigation</i> , 2004, 22, 954-954.   | 0.6 | 0         |
| 202 | Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 4523-4531.   | 0.8 | 122       |
| 203 | Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2962-2967.  | 3.2 | 41        |
| 204 | Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 93, 561-563.  | 0.6 | 18        |
| 205 | Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 147-159.   | 2.1 | 77        |
| 206 | Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. <i>Gynecologic Oncology</i> , 2003, 91, 584-590.  | 0.6 | 45        |
| 207 | The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, 431-434.   | 0.6 | 36        |
| 208 | Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. <i>Gynecologic Oncology</i> , 2003, 91, 123-129.  | 0.6 | 43        |
| 209 | Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy. <i>Gynecologic Oncology</i> , 2002, 84, 378-382.  | 0.6 | 95        |
| 210 | Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1238-1247. | 0.8 | 87        |
| 211 | Intrahepatic arterial infusion of chemotherapy: Clinical results. <i>Seminars in Oncology</i> , 2002, 29, 126-135.   | 0.8 | 32        |
| 212 | A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2505-11.  | 3.2 | 339       |